Home/Pipeline/NS-051/NCNP-04

NS-051/NCNP-04

Duchenne Muscular Dystrophy

Phase 1/2Active

Key Facts

Indication

Duchenne Muscular Dystrophy

Phase

Phase 1/2

Status

Active

Company

NS Pharma

About NS Pharma

NS Pharma is a private, clinical-stage biotech subsidiary of Japan's Nippon Shinyaku, headquartered in Paramus, New Jersey. The company is dedicated to advancing therapies for rare diseases, with a pipeline centered on exon-skipping oligonucleotides for Duchenne Muscular Dystrophy and a JAK1 inhibitor for eosinophilic granulomatosis with polyangiitis (EGPA). Its lead asset, brogidirsen (NS-089/NCNP-02), has reported multi-year clinical data, positioning the company in the competitive DMD landscape, while its platform extends to cell therapy research. NS Pharma operates as a strategic R&D arm, likely funded by its parent company, with a patient-centric mission driven by innovative science.

View full company profile

Therapeutic Areas

Neurological Diseases Inflammatory Diseases

Other Duchenne Muscular Dystrophy Drugs

Drug	Company	Phase	Status
MyoPAXon	Myogenica	Phase 1	Active
DMD Gene Therapy	Kinea Bio	Pre-clinical	Active
UCT-MSC + Biomaterials	Vitti Labs	Phase 2	Active
Myosana Platform for DMD	Myosana Therapeutics	Pre-clinical	Active
PEPR-124 (RT-001)	Peptris Technologies Private	Phase 2-ready	Licensed to Revio Therapeutics
DMD Genetic Screening Panel	Nanodigmbio	Commercial	Active
KHR‑001	KAHR Medical	Preclinical	Active
PF-06939926	Pfizer	Phase 3	Active